Skip to content

To assess and compare effectivity of dexamethasone and methylphenidate in cancer patient who have fatigue

A prospective interventional study to compare and assess the effectivity of dexamethasone and methylphenidate on cancer related fatigue at SMS medical college,Jaipur - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065257
Enrollment
200
Registered
2024-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: Drug dexamethasone and methylphenidate: To compare effectivity of methylphenidate and dexamethasone There will be two following groups 1. Dexamethasone group eligible subjects taking 8m

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 and above 2. Registered in palliative care centre 3. Suffering from histologically diagnosed advanced cancer 4. Patient with cancer related fatigue score greater than or equal to 4 to 10 on Edmonton symptoms assessment scale 5. Patient giving written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating female 2. Known history of hypersensitive to study drugs 3. History of AIDS 4. History of surgery in the last 2 weeks 5. Abnormal T3,T4,TSH 6. Anemia (Hb less than9) 7. Known case of Diabetes mellitus, Hypertension 8. Severe renal impairment, 9. Severe liver impairment, 10. Significant disorder of bone marrow 11. Cardiac conduction defect. 12. Patient taking Antipsychotic, sedative- psychotropic drug. Atropine and its substitute 13. Non co-operative patient 14. Patients who were not able to answer the questionnaires

Design outcomes

Primary

MeasureTime frame
1.FatigueTimepoint: Change in fatigue score will be assessed i.e 1 st week and 2 nd week

Secondary

MeasureTime frame
1.Effect on appetite 2.Effect on psychological symptoms 3. Adverse eventsTimepoint: 1.change in appetite will be assessed i.e. baseline, 1st week,2 nd week 2.change in effect of psychological symptoms will be assessed i.e. baseline, 1st week and 2nd week 3. Adverse events will be assessed i.e baseline,1 st week,2 nd week

Countries

India

Contacts

Public ContactDr.Ashwin Mathur

Sawai Man Singh medical college and attached hospital

drmathurashwin@gmail.com9829038756

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026